International Journal of Hematology

DOI: 10.1007/s12185-013-1290-3 Pages: 324-332

Histone deacetylase inhibitors in the treatment for multiple myeloma

1. Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute and Harvard Medical School, Department of Medical Oncology

Correspondence to:
Teru Hideshima
Tel: +1-617-6322559
Fax: +1-617-6322140
Email: teru_hideshima@dfci.harvard.edu

Close

Abstract

Histone lysine acetylation is regulated by both histone deacetylases (HDACs) and histone acetyl transferases. Inhibition of deacetylases induces hyperacetylate of target proteins and has a crucial role in the epigenetic regulation of gene expression mediating cell survival and proliferation. Therefore, HDAC inhibitors have emerged as novel therapeutic agents for cancers, including multiple myeloma (MM). Recent studies revealed that HDAC inhibitors trigger hyperacetylation of not only histones, but also non-histone proteins regulating cell growth and survival, revealing the complexity of mechanism of action of HDAC inhibitors. Many HDAC inhibitors have already shown significant anti-MM activities in preclinical studies and are under evaluation in clinical trials.

This article is freely available, click here to access the full text/PDF

Share the Knowledge